Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2013Cited by 66 (Europe PMC)

PMID23281041DOI10.1002/jbmr.1853PepBankPUB-23281041

Source link PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women previously receiving raloxifene, hip volumetric BMD increased after switching to teriparatide at 18 months but not at 6 months.
In plain wordsIn women previously receiving raloxifene, hip volumetric density increased from baseline after switching to teriparatide only at the later assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedHip volumetric BMD after switch from raloxifene
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
In the RLX stratum, hip vBMD and strength increased at 6 and 18 months in the Add group but only at 18 months in the Switch group (Strength, Month 18: 2.7% Add group, p < 0.01 and 3.4% Switch group, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
Report a problemFND-2328104107
02HumanRandomized controlled trialEfficacy outcome
In women previously receiving raloxifene, hip strength increased after switching to teriparatide at 18 months but not at 6 months.
In plain wordsIn women previously receiving raloxifene, hip strength increased from baseline after switching to teriparatide only at the later assessment.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedHip strength after switch from raloxifene
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 18 monthsAs given in this study (human).
Measurements
Hip strength increase
3.4%
raloxifene stratum, Switch group, month 18
Source sentences
Summary
In the RLX stratum, hip vBMD and strength increased at 6 and 18 months in the Add group but only at 18 months in the Switch group (Strength, Month 18: 2.7% Add group, p < 0.01 and 3.4% Switch group, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
Report a problemFND-2328104108
03HumanRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, hip volumetric BMD did not increase after switching to teriparatide.
In plain wordsIn women previously receiving alendronate, hip volumetric density did not increase from baseline after switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip volumetric BMD after switch from alendronate
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 18 monthsAs given in this study (human).
Measurements
Hip vBMD change
−0.5%
alendronate stratum, Switch group, month 6
Hip vBMD change
0%
alendronate stratum, Switch group, month 18
Source sentences
Summary
In the ALN stratum, hip vBMD increased in the Add but not in the Switch group (0.9% versus -0.5% at 6 months and 2.2% versus 0.0% at 18 months, both p ≤ 0.004 group difference).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
Report a problemFND-2328104110
04HumanRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, hip strength did not increase after switching to teriparatide at 18 months.
In plain wordsIn women previously receiving alendronate, hip strength did not increase from baseline after switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip strength after switch from alendronate
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/day · 18 monthsAs given in this study (human).
Measurements
Hip strength change
0%
alendronate stratum, Switch group, month 18
Source sentences
Summary
At 18 months, hip strength increased in the Add group (2.7%, p < 0.01) but not in the Switch group (0%); however, the difference between groups was not significant (p = 0.076).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
Report a problemFND-2328104113

Studies that did not test the peptide alone10

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine volumetric BMD increased from baseline across all teriparatide add and switch regimens.
In plain wordsIn women with osteoporosis, spine volumetric density increased from baseline across all teriparatide add and switch regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine volumetric BMD across regimens
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine vBMD median increase from baseline
13.2 to 17.5%
all groups; range reported jointly for vBMD and strength
Source sentences
Summary
At the spine, median vBMD and strength increased from baseline in all groups (13.2% to 17.5%, p < 0.01); there were no significant differences between the Add and Switch groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104101
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine strength increased from baseline across all teriparatide add and switch regimens.
In plain wordsIn women with osteoporosis, spine strength increased from baseline across all teriparatide add and switch regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine strength across regimens
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine strength median increase from baseline
13.2 to 17.5%
all groups; range reported jointly for vBMD and strength
Source sentences
Summary
At the spine, median vBMD and strength increased from baseline in all groups (13.2% to 17.5%, p < 0.01); there were no significant differences between the Add and Switch groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104102
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine volumetric BMD did not differ significantly between adding teriparatide and switching to teriparatide.
In plain wordsIn women with osteoporosis, spine volumetric density did not differ significantly between adding teriparatide and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine volumetric BMD add versus switch
Study
n: not reported in source
Comparator
Switch to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
At the spine, median vBMD and strength increased from baseline in all groups (13.2% to 17.5%, p < 0.01); there were no significant differences between the Add and Switch groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104103
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine strength did not differ significantly between adding teriparatide and switching to teriparatide.
In plain wordsIn women with osteoporosis, spine strength did not differ significantly between adding teriparatide and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine strength add versus switch
Study
n: not reported in source
Comparator
Switch to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
At the spine, median vBMD and strength increased from baseline in all groups (13.2% to 17.5%, p < 0.01); there were no significant differences between the Add and Switch groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104104
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving raloxifene, adding teriparatide increased hip volumetric BMD from baseline at both assessment times.
In plain wordsIn women previously receiving raloxifene, adding teriparatide increased hip volumetric density from baseline at both assessment times.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip volumetric BMD with raloxifene add regimen
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the RLX stratum, hip vBMD and strength increased at 6 and 18 months in the Add group but only at 18 months in the Switch group (Strength, Month 18: 2.7% Add group, p < 0.01 and 3.4% Switch group, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104105
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving raloxifene, adding teriparatide increased hip strength from baseline at both assessment times.
In plain wordsIn women previously receiving raloxifene, adding teriparatide increased hip strength from baseline at both assessment times.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip strength with raloxifene add regimen
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip strength increase
2.7%
raloxifene stratum, Add group, month 18
Source sentences
Summary
In the RLX stratum, hip vBMD and strength increased at 6 and 18 months in the Add group but only at 18 months in the Switch group (Strength, Month 18: 2.7% Add group, p < 0.01 and 3.4% Switch group, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104106
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, adding teriparatide increased hip volumetric BMD from baseline.
In plain wordsIn women previously receiving alendronate, adding teriparatide increased hip volumetric density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip volumetric BMD with alendronate add regimen
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip vBMD change
0.9%
alendronate stratum, Add group, month 6
Hip vBMD change
2.2%
alendronate stratum, Add group, month 18
Source sentences
Summary
In the ALN stratum, hip vBMD increased in the Add but not in the Switch group (0.9% versus -0.5% at 6 months and 2.2% versus 0.0% at 18 months, both p ≤ 0.004 group difference).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104109
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, adding teriparatide increased hip volumetric BMD more than switching to teriparatide at both assessment times.
In plain wordsIn women previously receiving alendronate, adding teriparatide increased hip volumetric density more than switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip volumetric BMD add versus switch after alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip vBMD change
0.9%
alendronate stratum, Add group, month 6
Hip vBMD change
−0.5%
alendronate stratum, Switch group, month 6
Hip vBMD change
2.2%
alendronate stratum, Add group, month 18
Hip vBMD change
0%
alendronate stratum, Switch group, month 18
Source sentences
Summary
In the ALN stratum, hip vBMD increased in the Add but not in the Switch group (0.9% versus -0.5% at 6 months and 2.2% versus 0.0% at 18 months, both p ≤ 0.004 group difference).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104111
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, adding teriparatide increased hip strength from baseline at 18 months.
In plain wordsIn women previously receiving alendronate, adding teriparatide increased hip strength from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip strength with alendronate add regimen
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip strength increase
2.7%
alendronate stratum, Add group, month 18
Source sentences
Summary
At 18 months, hip strength increased in the Add group (2.7%, p < 0.01) but not in the Switch group (0%); however, the difference between groups was not significant (p = 0.076).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104112
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women previously receiving alendronate, hip strength changes did not differ significantly between adding teriparatide and switching to teriparatide.
In plain wordsIn women previously receiving alendronate, hip strength changes did not differ significantly between adding teriparatide and switching to teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip strength add versus switch after alendronate
Study
n: not reported in source
Comparator
Switch from alendronate to teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Hip strength change
2.7%
alendronate stratum, Add group, month 18
Hip strength change
0%
alendronate stratum, Switch group, month 18
Source sentences
Summary
At 18 months, hip strength increased in the Add group (2.7%, p < 0.01) but not in the Switch group (0%); however, the difference between groups was not significant (p = 0.076).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, postmenopausal women with osteoporosis receiving ALN 70 mg/week (n = 91) or RLX 60 mg/day (n = 77) for ≥18 months were randomly assigned to add or switch to teriparatide 20 µg/day.
Summary · context
Quantitative computed tomography scans were performed at baseline, 6 months, and 18 months to assess changes in vBMD; strength was estimated by nonlinear finite element analysis.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2328104114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT04467983

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Hospital for Special Surgery, New Yorkn = 701 Feb 2021 to est. 31 Dec 2026

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 13 Oct 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.